EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mirum Pharmaceuticals's enterprise value is €1,142.1 Mil.
Mirum Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-117.8 Mil. Therefore, Mirum Pharmaceuticals's EV-to-EBITDA for today is -9.70.
The historical rank and industry rank for Mirum Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
FRA:08D'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.11 Med: -8.26 Max: -1.32
Current: -9.61
During the past 6 years, the highest EV-to-EBITDA of Mirum Pharmaceuticals was -1.32. The lowest was -21.11. And the median was -8.26.
FRA:08D's EV-to-EBITDA is ranked worse than 100% of 447
companies
in the Biotechnology industry
Industry Median: 9.48
vs FRA:08D: -9.61
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Mirum Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Mirum Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mirum Pharmaceuticals's EV-to-EBITDA
For the Biotechnology subindustry, Mirum Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mirum Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mirum Pharmaceuticals's EV-to-EBITDA falls into.
Mirum Pharmaceuticals's current Enterprise Value is €1,142.1 Mil.
Mirum Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-117.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Mirum Pharmaceuticals's PE Ratio for today is calculated as:
Mirum Pharmaceuticals's share price for today is €24.60.
Mirum Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.473.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Mirum Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Mirum Pharmaceuticals (FRA:08D) Business Description
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:08D has been successfully added to your 